Search for: "Boehringer Ingelheim Pharmaceuticals, Inc"
Results 81 - 100
of 124
Sorted by Relevance
|
Sort by Date
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
1 Aug 2013, 9:29 am
The generic and brand names of the drugs in this family include: • Exenatide (Byetta & Bydureon) marketed by Bristol Myers-Squibb and Amylin Pharmaceuticals, Inc. [read post]
1 Aug 2019, 8:30 am
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
6 Nov 2007, 5:55 am
Rosenbaum, District of MinnesotaNature of Suits: Consists of 58 actions against Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. arising from use of Mirapex, a treatment for Parkinson's disease, which alleged causes obsessive pleasure- and reward-seeking behavior, such as gambling.In re Kugel Mesh Hernia Patch Products Liability Litigation, MDL 1842Filed 2/28/07 and ordered to be transferred on 6/22/2007Transferee Judge and Court: Mary H. [read post]
15 Jun 2012, 2:51 pm
Pradaxa Approved by FDA in 2010 and Investigated by 2011 In 2010, the United States Food & Drug Administration (FDA) approved Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., as a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. [read post]
15 Jun 2012, 2:51 pm
Pradaxa Approved by FDA in 2010 and Investigated by 2011 In 2010, the United States Food & Drug Administration (FDA) approved Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc., as a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. [read post]
11 Jan 2024, 12:03 am
The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer. [read post]
13 May 2010, 4:58 pm
Watson Pharmaceuticals Inc. et al. [read post]
27 May 2010, 3:20 am
Boehringer Ingelheim International GMBH et al. [read post]
12 Jan 2012, 4:21 am
The IPKat has always been unhappy at the bit in Case C-348/04 Boehringer Ingelheim KG v Swingward Ltd: where the Court of Justice of the European Union said: "Where a parallel importer has failed to give prior notice to the trade mark proprietor concerning a repackaged pharmaceutical product, he infringes that proprietor’s rights on the occasion of any subsequent importation of that product, so long as he has not given the proprietor such notice. [read post]
2 Nov 2012, 11:58 am
Boehringer Ingelheim Pharmaceuticals, Inc., 2009 WL 702007, at *3-4 (D. [read post]
17 Mar 2015, 3:09 am
Boehringer Ingelheim Pharmaceuticals, Inc.). [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
22 May 2009, 9:32 am
Flomax is manufactured by Boehringer Ingelheim Pharmaceuticals Inc. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
8 Jul 2015, 8:31 am
Labs., Inc., 625 F.2d 1055 (3d Cir. 1980) (holding unique coloring of prescription drug capsule constituted protectable trade dress); Boehringer Ingelheim G.m.b.H. v. [read post]
16 Feb 2015, 3:44 am
Boehringer Ingelheim Pharmaceuticals, Inc., D. [read post]
5 Jun 2014, 7:06 am
Boehringer Ingelheim Pharmaceuticals, Inc., which was decided just a few months before I started my career in employment law. [read post]
28 Jul 2013, 9:29 am
Some of the other diabetes drugs being investigated include Bydureon and Onglyza, sold by Bristol-Myers Squibb; AstraZeneca and Victoza from Novo Nordisk; Tradjenta from Eli Lilly and Boehringer Ingelheim; and Nesina from Takeda. [read post]
